Clinical evaluation of satigrel in intermittent claudicators.

Abstract

OBJECTIVE:

Satigrel is a new antiplatelet agent which was previously shown to inhibit platelet aggregation and have an anti-thrombotic effect in various animal thrombosis models. The present study assessed the effect of oral satigrel on cutaneous circulation in patients with intermittent claudication due to arteriosclerosis obliterans.

EXPERIMENTAL DESIGN:

Prospective clinical trial with more than 4 weeks follow-up.

SETTING:

Outpatient department of a university hospital.

PATIENTS:

Ten patients with intermittent calf claudication were studied (14 limbs with obstruction, 6 limbs without obstruction, and chest wall).

INTERVENTIONS:

After giving informed consent and one week wash-out of effected agents, a 2 mg oral dose of satigrel twice daily was administered for more than 4 weeks.

MEASURES:

Transcutaneous partial pressure of oxygen (PtcO2), skin temperature, ankle pressure, and the treadmill test were determined just before therapy, after 2 and 4 weeks of satigrel therapy, and at treatment termination. The paired student's t-test was used for statistical analysis.

RESULTS:

The PtcO2 in the foot of the ischemic leg showed a significant increase at the end of therapy compared with before therapy (p < 0.05). Skin temperature showed a significant difference in both the ischemic and healthy legs. The walking distance was also significantly extended at therapy termination.

CONCLUSIONS:

Satigrel improved the cutaneous circulation and symptoms of patients with intermittent claudication.

• Authors: T Iwai, S Qian
• Journal: Panminerva medica (Panminerva Med) Vol. 38 Issue 4 Pg. 243-8 (Dec 1996) ISSN: 0031-0808 [Print] Italy
• PMID: 9063033 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Fatty Acids, Monounsaturated
• Platelet Aggregation Inhibitors
• Satigrel

Topics

• Adult
• Aged
• Exercise Test
• Fatty Acids, Monounsaturated (therapeutic use)
• Humans
• Intermittent Claudication (drug therapy)
• Male
• Middle Aged
• Platelet Aggregation Inhibitors (therapeutic use)
• Prospective Studies